These data represent a needed scientific advancement with the potential to reduce the risk of cardiovascular events such as heart attacks or strokes with a once-daily pill." Lilly is evaluating ...
The results from the SUMMIT trial of tirzepatide in obese patients with heart failure with preserved ejection fraction (HFpEF) showed that Lilly’s drug cut the risk of cardiovascular mortality and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback